TOP2A (DNA topoisomerase 2-alpha)

Compared with amplification, oncogenic ERBB2 mutations are preferentially associated with higher TMB/MSI-H and characteristic co-mutation signatures, supporting the clinical evaluation of mutation-selective HER2 inhibitors and rational combinations with immune checkpoint blockade. Our findings expand the molecular epidemiology of ERBB2 in Chinese GI cohorts, suggesting potential implications for resistance to standard chemotherapy or anti-EGFR strategies in select settings.

The algorithm successfully identifies key biomarkers, including LPL, LEP, CD36, CDC20, TOP2A, and EZH2, significantly improving breast cancer detection accuracy and reducing false positives, achieving an impressive F1 score of 98.958%. These biomarkers provide critical insights into important pathways, such as AMPK and PPAR signaling, setting a new benchmark in computational biology and bioinformatics research, and paving the way for advancements in diagnostic techniques and medical science.

This study identified TPX2, CCNB2, BUB1, TOP2A, and ASPM as potential candidate diagnostic biomarkers for GEJAC at the transcriptomic level. These genes are closely associated with immune cell infiltration, providing new insights into GEJAC pathogenesis and potential targets for immunotherapy.

The cardiomyocyte-specific, tamoxifen-inducible TOP2B transgenic mice exhibited pathophysiological features consistent with doxorubicin-induced cardiotoxicity, even without exposure to anthracyclines. Our findings reveal a novel role for TOP2B in AIC, demonstrating that its upregulation disrupts SMYD1 function in cardiomyocytes, contributing to cardiotoxicity. This study also highlights the therapeutic potential of targeting TOP2B using ASO for preventing AIC in cancer patients, offering new insights into cardioprotective strategies.

This study established a novel therapeutic strategy for treating the two major lung cancer subtypes by DHA and CRS combination at lower concentrations. The discovery of TOP2A as a therapeutic target opens new avenues for drug discovery, potentially expanding the development of TOP2A-targeted therapies.

Here, we present a simple qPCR-based 10-gene mRNA test, qMIDSNPC, with potential clinical utilities for rapid (1 h) prognostic stratification of NPC. Further studies involving geographically and ethnically independent NPC cohorts would be needed to validate the clinical use of qMIDSNPC in non-endemic NPC populations.

Phosphorylated TOP1, TOP2A, TOP2B, and C1orf35 are strongly associated with HCC progression and poor prognosis, highlighting their potential as prognostic biomarkers and therapeutic targets. These insights not only enhance our understanding of the complex molecular mechanisms underlying HCC but also offer promising avenues for the identification of novel therapeutic targets.

CUT&Tag and RT-qPCR revealed that p53 binds to a specific region (-200 to -249 bp) of TSP50 promotor, leading to transcriptional repression. Our findings delineate a novel TOP2α/MDM2/p53/TSP50 axis in SKCM and propose etoposide as a precision therapy for TSP50-overexpressing melanomas.

4'-Demethyl-epipodophyllotoxin (4'-DMEP) is a precursor of etoposide and has attracted much attention due to its significant antitumor activity...In vitro experiments revealed that 4'-DMEP inhibited A549 cell proliferation by inducing cell cycle arrest and apoptosis, with significant changes in the expression of SLC2A1, TOP2A, and MIF. These findings not only clarify its molecular mechanism but also provide new ideas for the precise treatment of lung adenocarcinoma.

p53-R248W confers selective doxorubicin resistance to multiple cancer cells through TOP2A suppression and CYP1A1/A2 overexpression. These findings highlight the mutation specific mechanism of doxorubicin resistance that might result in poor response and needs to be considered during treatment plan.

As the signature relies exclusively on IHC, it is simple, cost-effective and readily integratable into routine diagnostic workflows. In addition to its prognostic value, several biomarkers within the panel are potentially actionable, offering opportunities to guide targeted therapies in patients predicted to have poor response to conventional chemotherapy.

Future directions emphasize integrating antigen discovery with immune profiling, refining preclinical modeling, and developing personalized vaccines to enhance therapeutic efficacy, particularly for immunologically favorable patient subtypes and for certain applications such as reducing metastasis after surgery. In particular, we discuss carrier-based vaccine approaches for overcoming tolerance and increasing the immunogenicity of vaccines.